Rifampicin-resistant Mycobacterium tuberculosis: Susceptibility to isoniazid and other anti-tuberculosis drugs

Ekaterina V. Kurbatova; J. S. Cavanaugh; N. S. Shah; A. Wright; H. Kim; B. Metchock; A. Van Deun; L. Barrera; F. Boulahbal; E. Richter; N. Martín-Casabona; F. Arias; I. Zemanova; F. Drobniewski; A. Santos Silva; C. Coulter; R. Lumb; J. P. Cegielski

doi:10.5588/ijtld.11.0542

Rifampicin-resistant Mycobacterium tuberculosis: Susceptibility to isoniazid and other anti-tuberculosis drugs

Ekaterina V. Kurbatova^*
, J. S. Cavanaugh
, N. S. Shah
, A. Wright
, H. Kim
, B. Metchock
, A. Van Deun
, L. Barrera
, F. Boulahbal
, E. Richter
, N. Martín-Casabona
, F. Arias
, I. Zemanova
, F. Drobniewski
, A. Santos Silva
, C. Coulter
, R. Lumb
, J. P. Cegielski

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

34 Citations (Scopus)

Abstract

Based on data from 14 Supranational Tuberculosis (TB) Reference Laboratories worldwide, the proportion of rifampicin (RMP) resistant isolates that were isoniazid (INH) susceptible by phenotypic drug susceptibility testing varied widely (0.5-11.6%). RMP-resistant isolates that were INH-susceptible had significantly lower rates of resistance to other first- and second-line anti-tuberculosis drugs (except rifabutin) compared to multidrug-resistant isolates. RMP resistance is not a lways a good proxy for a presumptive diagnosis of multidrug-resistant TB, which has implications for use of molecular assays that identify only RMP resistanceassociated DNA mutations.

Original language	English
Pages (from-to)	355-357
Number of pages	3
Journal	International Journal of Tuberculosis and Lung Disease
Volume	16
Issue number	3
DOIs	https://doi.org/10.5588/ijtld.11.0542
Publication status	Published - 1 Mar 2012

Bibliographical note

Copyright:
Copyright 2013 Elsevier B.V., All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Drug resistance
Molecular diagnostic tests
Rifampicin resistance
Tuberculosis

Access to Document

10.5588/ijtld.11.0542

Cite this

Kurbatova, E. V., Cavanaugh, J. S., Shah, N. S., Wright, A., Kim, H., Metchock, B., Van Deun, A., Barrera, L., Boulahbal, F., Richter, E., Martín-Casabona, N., Arias, F., Zemanova, I., Drobniewski, F., Santos Silva, A., Coulter, C., Lumb, R., & Cegielski, J. P. (2012). Rifampicin-resistant Mycobacterium tuberculosis: Susceptibility to isoniazid and other anti-tuberculosis drugs. International Journal of Tuberculosis and Lung Disease, 16(3), 355-357. https://doi.org/10.5588/ijtld.11.0542

@article{a62cedf99a7545b99b6d39f8c0c441c0,

title = "Rifampicin-resistant Mycobacterium tuberculosis: Susceptibility to isoniazid and other anti-tuberculosis drugs",

abstract = "Based on data from 14 Supranational Tuberculosis (TB) Reference Laboratories worldwide, the proportion of rifampicin (RMP) resistant isolates that were isoniazid (INH) susceptible by phenotypic drug susceptibility testing varied widely (0.5-11.6\%). RMP-resistant isolates that were INH-susceptible had significantly lower rates of resistance to other first- and second-line anti-tuberculosis drugs (except rifabutin) compared to multidrug-resistant isolates. RMP resistance is not a lways a good proxy for a presumptive diagnosis of multidrug-resistant TB, which has implications for use of molecular assays that identify only RMP resistanceassociated DNA mutations.",

keywords = "Drug resistance, Molecular diagnostic tests, Rifampicin resistance, Tuberculosis",

author = "Kurbatova, \{Ekaterina V.\} and Cavanaugh, \{J. S.\} and Shah, \{N. S.\} and A. Wright and H. Kim and B. Metchock and \{Van Deun\}, A. and L. Barrera and F. Boulahbal and E. Richter and N. Mart{\'i}n-Casabona and F. Arias and I. Zemanova and F. Drobniewski and \{Santos Silva\}, A. and C. Coulter and R. Lumb and Cegielski, \{J. P.\}",

year = "2012",

month = mar,

day = "1",

doi = "10.5588/ijtld.11.0542",

language = "English",

volume = "16",

pages = "355--357",

journal = "International Journal of Tuberculosis and Lung Disease",

issn = "1027-3719",

publisher = "International Union Against Tuberculosis and Lung Disease ",

number = "3",

}

Kurbatova, EV, Cavanaugh, JS, Shah, NS, Wright, A, Kim, H, Metchock, B, Van Deun, A, Barrera, L, Boulahbal, F, Richter, E, Martín-Casabona, N, Arias, F, Zemanova, I, Drobniewski, F, Santos Silva, A, Coulter, C, Lumb, R & Cegielski, JP 2012, 'Rifampicin-resistant Mycobacterium tuberculosis: Susceptibility to isoniazid and other anti-tuberculosis drugs', International Journal of Tuberculosis and Lung Disease, vol. 16, no. 3, pp. 355-357. https://doi.org/10.5588/ijtld.11.0542

TY - JOUR

T1 - Rifampicin-resistant Mycobacterium tuberculosis

T2 - Susceptibility to isoniazid and other anti-tuberculosis drugs

AU - Kurbatova, Ekaterina V.

AU - Cavanaugh, J. S.

AU - Shah, N. S.

AU - Wright, A.

AU - Kim, H.

AU - Metchock, B.

AU - Van Deun, A.

AU - Barrera, L.

AU - Boulahbal, F.

AU - Richter, E.

AU - Martín-Casabona, N.

AU - Arias, F.

AU - Zemanova, I.

AU - Drobniewski, F.

AU - Santos Silva, A.

AU - Coulter, C.

AU - Lumb, R.

AU - Cegielski, J. P.

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Based on data from 14 Supranational Tuberculosis (TB) Reference Laboratories worldwide, the proportion of rifampicin (RMP) resistant isolates that were isoniazid (INH) susceptible by phenotypic drug susceptibility testing varied widely (0.5-11.6%). RMP-resistant isolates that were INH-susceptible had significantly lower rates of resistance to other first- and second-line anti-tuberculosis drugs (except rifabutin) compared to multidrug-resistant isolates. RMP resistance is not a lways a good proxy for a presumptive diagnosis of multidrug-resistant TB, which has implications for use of molecular assays that identify only RMP resistanceassociated DNA mutations.

AB - Based on data from 14 Supranational Tuberculosis (TB) Reference Laboratories worldwide, the proportion of rifampicin (RMP) resistant isolates that were isoniazid (INH) susceptible by phenotypic drug susceptibility testing varied widely (0.5-11.6%). RMP-resistant isolates that were INH-susceptible had significantly lower rates of resistance to other first- and second-line anti-tuberculosis drugs (except rifabutin) compared to multidrug-resistant isolates. RMP resistance is not a lways a good proxy for a presumptive diagnosis of multidrug-resistant TB, which has implications for use of molecular assays that identify only RMP resistanceassociated DNA mutations.

KW - Drug resistance

KW - Molecular diagnostic tests

KW - Rifampicin resistance

KW - Tuberculosis

UR - https://www.scopus.com/pages/publications/84863123196

U2 - 10.5588/ijtld.11.0542

DO - 10.5588/ijtld.11.0542

M3 - Article

C2 - 22640449

AN - SCOPUS:84863123196

SN - 1027-3719

VL - 16

SP - 355

EP - 357

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

IS - 3

ER -

Rifampicin-resistant Mycobacterium tuberculosis: Susceptibility to isoniazid and other anti-tuberculosis drugs

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this